CFO departure

Celldex Therapeutics, Inc. discloses CFO departure: Sam Martin

Celldex Therapeutics, Inc. reported in a Form 8-K filed July 15, 2026 a change involving its Chief Financial Officer, Sam Martin, effective March 31, 2027. The filing's own words are quoted below.

In the filing's words

On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the Company of his plans to retire effective on or about March 31, 2027.

Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.

Company	Celldex Therapeutics, Inc. (CLDX)
Event	Departure
Outgoing	Sam Martin
Effective	March 31, 2027
8-K filed	July 15, 2026
SEC CIK	0000744218

Celldex Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed July 15, 2026. The filing's own words are quoted above.

Other records naming Sam Martin

The outgoing officer on this record, matched by name. Career line.

2026-02-25 · 10-K signature

Sam Martin signed Celldex Therapeutics, Inc.'s annual report as Senior Vice President, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)

Also filed in July 2026

Other CFO moves on the record that month. All moves.

3 months ago· 2026-07-31DepartureARAI

Arrive AI Inc. discloses CFO departure: Todd Pepmeier

3 months ago· 2026-07-31TransitionMAYS

J.W. Mays, Inc. CFO transition: Kevin Guptar to succeed Ward Lyke, Jr.

3 months ago· 2026-07-31AppointmentQNCX

Quince Therapeutics, Inc. appoints John Militello as CFO

3 months ago· 2026-07-31AppointmentGCAN

The Greater Cannabis Company, Inc. appoints Michelle Cervantes Vivanco as CFO

3 months ago· 2026-07-31DepartureTG

Tredegar Corporation discloses CFO departure: Frasier W. Brickhouse, II

3 months ago· 2026-07-30DepartureCBT

Cabot Corporation discloses CFO departure: Erica McLaughlin

Sources

sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26

Something wrong about Sam Martin? Send a correction with the primary source.